The Pharmacoeconomic Analysis of Collost Bioplastic Material in Patients with Diabetic Foot
The aim of the study was to evaluate cost-effectiveness of the Collost medical device in usual clinical practice for the treatment of Wagner II diabetic foot ulcers (DFU) wound surface area > 10 cm<sup>2</sup>. Material and methods. The results of post-authorization multicenter comparative study on the use of Collost biomaterial in the treatment of DFU were considered; direct medical costs of the compared treatments were assessed; a comparative pharmacoeconomic analysis of alternative treatment tactics was conducted. Results. The results of pharmacoeconomic study showed that the standard inpatient treatment of ulcerous defects with the use of Collost biomaterial was cost effective. This conclusion was based on CER, ICER, calculations and sensitivity analysis.